ArticleCancer diagnosis & prognosis
Patient-reported Symptoms Differ Between Patients With Brain Metastasis Starting Either Focal Stereotactic Radiotherapy or Whole-brain Radiotherapy.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: The presence of brain metastasis is often associated with clinical symptoms and reduced quality-of life scores, potentially triggering palliative care needs. Previous studies have employed the Edmonton symptom assessment system (ESAS) to this end. However, contemporary patient-reported ESAS data from cohorts managed with different radiotherapy techniques rather than whole-brain radiotherapy (WBRT) alone are scarce. Therefore, the aim of this study was to compare ESAS symptom severity before WBRT to that before stereotactic radiosurgery or fractionated radiotherapy (SRS/FSRT). Materials and Methods: This was a retrospective analysis (2013-2024, n=102) of patients with brain metastasis assessed with ESAS in routine clinical practice in Norway. Patients were stratified based on radiotherapy approach (WBRT±boost Results: For the whole study group, fatigue and overall wellbeing scores were highest (mean 3.9 and 3.4, respectively). The lowest scores were those for nausea and constipation (mean 1.2 and 1.4, respectively). Within the WBRT cohort, no significant differences were observed between ESAS scores of boost Conclusion: When employing ESAS screening to provide additional palliative care services to patients with brain metastasis who start radiotherapy, clinicians should be aware of the fact that patients undergoing WBRT may have worse symptom burden and higher needs than patients undergoing SRS/FSRT. This is particularly evident for anxiety, fatigue and overall wellbeing, and not explained by differences in number of brain metastasis and diagnostic setting (regular imaging surveillance
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.